Back in August I posted about a new drug that was being developed here in New Jersey that was thought to be a promising new treatment for traumatic brain injuries. The drug, dexanabinol was developed by Pharmos and had thought to be able to assist in minimizing the damage caused by a traumatic brain injury by preventing swelling of the brain. Unfortunately today it was announced that in the Phase-3 trial of dexanabinol, the drug failed to show statistically significant improvement in a patient’s ability to regain more of their memory and other high-level function following a severe blow to the head. You can read more about this story here.